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Lipoprotein-stimulated mesangial cell proliferation and gene glomerular disease [1]. Hyperlipidemia has been identified
expression are regulated by lipoprotein lipase. as an independent risk factor for the progression of renal
Background. Hyperlipidemia accelerates the progression of disease in both diabetic and nondiabetic glomerular dis-glomerular disease, and lipoproteins bind glomerular mesan-
ease [2]. In vitro studies have shown that both nativegial cells (MC) and induce proliferation and cytokine expres-
and oxidized lipoproteins bind to and cause proliferationsion. In the vessel wall, the binding of lipoproteins to endothe-
lial cells is markedly enhanced by lipoprotein lipase (LpL), of glomerular cells [3, 4]. Understanding the mechanisms
synthesized by the underlying smooth muscle cells. While it is whereby lipids augment glomerular proliferation and in-
known that LpL is localized to the glomerulus, it is not known flammation is an important unresolved question of clini-if and how it modulates the lipoprotein–mesangial interaction.
cal relevance.Methods. Very low-density lipoprotein (VLDL) was isolated
Lipoprotein–cellular interactions have been most exten-from rats and was used to treat cultured primary rat MCs. Bind-
ing studies were done with and without LpL and with/without sively studied in the vessel wall. Lipoproteins are known
pretreatment with heparanase, which degrades cell surface hep- to bind to vascular endothelial cells via specific receptors:
aran sulfate proteoglycan (HSPG), known to modulate the low-density lipoprotein receptor (LDLr), very low-den-LpL–lipoprotein interaction in blood vessels. VLDL/LpL was
sity lipoprotein receptor (VLDLr), low-density lipopro-also used to assess MC proliferation and gene expression of
tein receptor-related protein (LRP), and gp330 (megalinthe cytokine platelet-derived growth factor (PDGF).
Results. LpL enhanced VLDL binding to MCs by as much receptor). These binding events lead to cellular prolifera-
as 200-fold, and most of this effect was blocked by pretreatment tion and altered synthesis of growth factors such as plate-
with heparanase. LpL amplified VLDL-driven MC prolifera- let-derived growth factor (PDGF), which in turn lead totion and increased VLDL-induced PDGF expression. Hep-
the progression of the atherosclerotic lesion in the vesselaranase pretreatment of cells eliminated both of these amplifi-
wall. The binding of lipoproteins to their receptors iscations. LpL alone increased MC proliferation and PDGF gene
expression. significantly enhanced by the interaction of lipoprotein
Discussion. As in the vessel wall, LpL enhances VLDL bind- lipase (LpL) with ligand, receptor, and cell-surface asso-
ing to MCs. MCs respond to LpL binding by proliferating and ciated heparan sulfate proteoglycans (HSPGs). This LpL
expressing cytokines such as PDGF. LpL may be a crucial
activity is distinct from its familiar catalytic role in triglyc-paracrine mediator of the glomerular response to circulating
eride hydrolysis on capillary walls. HSPGs are ubiquitouslipoproteins, amplifying a response that includes cytokine elab-
components of cell membranes and anchor a variety oforation, influx of circulating monocytes, and eventual sclerosis.
substrates to the cell, including basic fibroblast growth
factor (bFGF) and interferon-g [5]. At low-particle con-
centrations, most apoE-containing lipoprotein uptake isIt is now increasingly accepted that hyperlipidemia in
via the LDL receptor, but at higher particle concentra-humans is a contributing factor to the progression of a
tions, internalization comes via receptor-independentvariety of glomerular diseases, and treatment of hyperlip-
HSPG-mediated pathways [6]. It is these latter uptakeidemia is an important component in the management of
pathways that are felt to be most enhanced by LpL. LpL
is anchored to the cell surface, tethered to both HSPG
1 See Editorial by Harris, p. 2368. and lipoprotein receptors by noncatalytic, C-terminal
binding regions [6]. LpL binds lipoproteins, possibly viaKey words: hyperlipidemia, progressive renal disease, glomerular scle-
rosis, paracrine mediator, inflammation. their fatty acid component [7], and enhances their associ-
ation with the lipoprotein receptors [8].Received for publication March 14, 2000
While LpL and HSPG are expressed in glomeruli [9],and in revised form October 27, 2000
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protein interactions is unknown. In the case of LpL, theÓ 2001 by the International Society of Nephrology
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cellular origin of the enzyme in the glomerulus is not and dialyzed against two exchanges of phosphate-buf-
fered saline (PBS) for 24 hours. Because we found thatknown, as the glomerulus lacks the smooth muscle cells
that are the synthetic site in the vasculature. Previous the VLDL fraction contained small amounts of albumin,
VLDL to be radiolabeled was subject to additional cen-studies of lipoprotein–glomerular cell interactions have
not included manipulations of HSPG or LpL. Mesangial trifugal flotation [16]. Samples of VLDL before and after
this flotation step were electrophoresed on sodium dode-cells (MCs) in vitro proliferate when exposed to VLDL,
LDL, and VLDL remnants [3, 10], and take up LDL in a cyl sulfate (SDS)-polyacrylamide gels and scanned using
a STORM imager (Molecular Dynamics, Sunnyvale, CA,manner consistent with specific receptor mediation [11].
These cells also express lipoprotein receptors LDLr, USA) and staining with the fluorescent marker SYPRO
orange. This stain was selected because of its uniformVLDLr, and LRP in MCs and gp330 in podocytes [6].
Since LpL increases binding of lipoproteins to endothe- staining regardless of protein structure. The images were
analyzed using ImageQuant software (Molecular Dy-lial cells, we felt that there may be an important role
for this enzyme in mediating the mesangial proliferative namics). A faint albumin band (66 kD) detected in the
primary VLDL preps was not detected in VLDLs thatresponse, a prelude to many glomerular diseases. It could
also potentially amplify the proproliferative actions of were labeled. VLDL was stored under helium and used
within 14 days of collection.other inflammatory growth factors such as interleukin-1
or PDGF on the MC [12]. Given the importance of LpL
Radiolabeling of VLDLand HSPG in amplifying the binding of lipoproteins to
the vascular endothelium, we hypothesized that they Very low-density lipoproteins were radiolabeled with
125I according to the method of McFarlane as modifiedwould play an equally critical role in modulating lipopro-
tein–MC interactions. We also wondered whether these by Helmkamp, Contreras, and Bale [17]. Labeled VLDL
were dialyzed exhaustively with PBS, pH 7.4, until themolecules would also play an important role in lipopro-
tein-mediated proliferation, rather than just the uptake trichloroacetic acid precipitable counts were greater than
95% total.of lipid. Therefore, we designed experiments to quanti-
tate the importance of LpL and HSPG in modulating
Isolation of LpLthe binding, proliferation, and inducible cytokine gene
expression of cultured MCs in response to VLDL. Lipoprotein lipase was purified using the methods of
Liu and Olivecrona [18]. LpL was prepared from fresh
raw milk by affinity chromatography on heparin-Sepha-
METHODS
rose (Amersham Pharmacia Biotech, Piscataway, NJ,
Mesangial cells USA). Fractions with an optical density of $(0.200 AU)
at 280 nm were subsequently analyzed by SDS-polyacryl-Glomeruli from Sprague-Dawley rats were isolated by
differential sieving, and primary MCs were isolated and amide gel electrophoresis (SDS-PAGE), and fractions
containing a single darkly-stained band at 55 kD werecharacterized as described [13]. MCs grow from plated
glomeruli by 7 to 10 days; cells are characterized after pooled. The pool was assayed for activity and total protein.
In cell proliferation and gene expression studies, thetwo passages by contractility to angiotensin II and by
staining with anti-smooth muscle. Cells were used be- enzyme was denatured by incubation at 558C for 30 min-
utes to eliminate enzymatic activity. In subsequent stud-tween passages 5 and 9 and were grown in media con-
sisting of RPMI-1640 with 20% fetal bovine serum (FBS), ies, LpL was used at a concentration of 3 to 12 mg/mL,
a concentration in the linear portion of the binding re-0.66 IU/mL bovine insulin, 100 U/mL penicillin G, and
100 mg/mL streptomycin sulfate. sponse in other cell types [19]. The LpL was free of
lipopolysaccharide activity, as determined by Pyrotell
Isolation of VLDL limulus amebocyte lysate gel clot test from Associates
of Cape Cod, Inc. (Falmouth, MA, USA).Blood was obtained from eight-week-old female Zucker
rats by cardiac puncture under anesthesia. Plasma was
Protein quantitationhandled using the method recommended by Edelstein
and Scanu [14]. Blood was collected in ethylenediamine- Total proteins were measured using bicinchoninic acid
protein assay (Pierce).tetraacetic acid (EDTA) and centrifuged for 10 minutes
at 3000 3 g to remove red blood cells. VLDL was then
VLDL bindingisolated using sequential flotation [15]. Plasma was lay-
ered under a 1.0063 g/mL density solution of 1.05% NaCl For binding studies, rat primary MCs at passages 5 to 9
were plated into 48-well plates, and experiments wereand 0.27 mmol/L EDTA, and centrifuged at 200,000 3
g for 20 hours at 48C. The upper layer (up to 25% of the performed on confluent cells. Media containing Dul-
becco’s modified Eagle’s medium (DMEM), 25 mmol/Lvolume) was removed, injected into a 10,000 molecular
weight cutoff dialysis cassette (Pierce, Rockford, IL, USA), HEPES, pH 7.4, and lipoprotein-deficient FBS were used
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to prepare appropriate concentrations of labeled and (GIBCO/BRL, Rockville, MD, USA) according to the
manufacturer’s protocol, digested with DNase I (GIBCO/unlabeled VLDL. Prior to assaying binding, some wells
were incubated with 1.0 U/mL heparanase (Seikagaku, BRL), and reverse transcribed with Maloney murine leu-
kemia virus (MMLV) reverse transcriptase (GIBCO/BRL).Ijamsville, MD, USA) for one hour at 378C [20]. To
solutions containing 0.5 mg/mL 125I-labeled VLDL, unla- Quantitative polymerase chain reaction (PCR) was
carried out in a GeneAmp 5700 sequence detection sys-beled VLDL was added to achieve total VLDL protein
concentrations of between 0.5 and 40 mg/mL. Some wells tem (PE Biosystems, Foster City, CA, USA) using SYBR
Green I nucleic acid stain (Molecular Probes, Eugene,also contained 3 mg/mL LpL. Wells containing a total
of 300 mg/mL VLDL protein were used to assess nonspe- OR, USA) for the detection of double-stranded DNA.
Reactions (N 5 3 to 4 per experiment) were carried outcific binding. Forty-eight–well plates were removed from
incubators and allowed to cool on ice for 30 minutes; in 96-well plates in a volume of 50 mL containing 4 mL
diluted cDNA, 0.2 mmol/L forward and reverse primers,0.125 mL of VLDL media was added to wells, and each
concentration was assayed in triplicate. Plates were gen- 0.2 mmol/L dNTPs, 10 pg/mL tRNA, 1.5 mmol/L MgCl2,
5 mL SYBR Green I diluted 1:10,000 in dimethylsulfox-tly shaken for five hours at 48C. The cells were then
rinsed three times with PBS 1 2 mg/mL bovine serum ide, PCR buffer, and 1.25 U HotStarTaq Taq polymerase
(Qiagen, Valencia, CA, USA). After 15 minutes of incu-albumin (BSA) at 48C, incubated two times for 10 min-
utes with PBS-BSA at 48C, and rinsed two times with bation at 958C to activate the HotStarTaq, samples were
cycled 40 times at 948C for 30 seconds, 568C for 30 sec-PBS at 48C. Finally, the cells were dissolved in 0.25 mL
0.1 mol/L NaOH and read on Packard gamma counter. onds, and 728C for 75 seconds. Primer sequences for
PDGF A chain were forward, 59-AAG CAT GTG CCA
Cell proliferation GAG AAG CG-39, and reverse, 59-TCC TCT AAC CTC
ACC TGG AC-39 (305 bp product). Primer sequencesPrimary rat MCs were grown to 50 to 70% confluence
as described previously in this article in black 96-well for G3PDH were forward, 59-TGT ATC CGT TGT GGA
TCT GAC ATG C-39, and reverse, 59-CCC TGT TGCplates with transparent bottoms (Costar Corning, Corn-
ing, NY, USA). Cells were washed with PBS and then TGT AGC CAT ATT CAT TGT C-39 (254 bp product).
At the end of cycling, a threshold fluorescence valuequiesced for 24 hours in rest medium. The rest medium
used for the cell proliferation experiment was the same as was selected from the amplification plots obtained from
the GeneAmp 5700 software, within the exponentialgrowth media except that it contained 0.5% lipoprotein-
deficient FBS (Sigma CPSR-1) instead of 20% FBS. Cells phase of amplification of both gene products. The cycle
number at the fluorescence threshold, Ct, was then deter-were then incubated for 24 hours in rest media alone
or rest media containing VLDL (3 to 24 mg/mL) or mined for each gene product. PDGF-A Cts were normal-
ized for the amount of input cDNA by subtracting theVLDL 1 0 to 12 mg/mL denatured LpL. Ten-percent
fetal calf serum (FCS) was used as a positive proliferation Ct for G3PDH from the Ct for PDGF-A, giving a value
of DCt for each sample. Since the PCR product yieldcontrol. Some cells also were treated with bacterial he-
paranase as described previously in this article. Addi- doubles with each cycle during the exponential phase of
amplification, the relative abundance for each sample istional groups were treated with 50 mg/mL of an anti-
PDGF antibody (R&D, Minneapolis, MN, USA). At the calculated as 2DCt.
end of the incubation, media were removed. The cells
Statistical analysisfreeze-thawed twice and then incubated one hour in lysis
buffer containing Quantos DNA fluorescent dye reagent Data were analyzed using GraphPad Prism, version 2.01
(San Diego, CA, USA). Data are presented as mean 6(Stratagene, La Jolla, CA, USA). Fluorescence was mea-
sured from the bottom of the plate on a Packard Instru- SEM. Data were first analyzed for normal distribution.
They were then analyzed for differences using one-wayments (Meriden, CT, USA) FluoroCount microplate
reader set to 360 nm excitation and 460 nm emission. analysis of variance (ANOVA), with a post hoc analysis
using a Tukey test for multiple comparisons. Differences
PDGF-A chain mRNA expression were considered statistically significant at P , 0.05.
Cells were grown to 50 to 70% confluence in six-well
cluster plates and quiesced as with cell proliferation.
RESULTS
Cells were treated for eight hours with rest media alone
LpL enhances lipoprotein binding to mesangial cellsor rest media containing 5 mg/mL VLDL and/or 5 mg/mL
via a heparan sulfate-dependent mechanismLpL. The rest media for PDGF expression was DMEM
containing 0.05% BSA, 25 mmol/L HEPES, 5 mg/mL Very low-density lipoprotein was isolated from hyper-
triglyceridemic obese Zucker rats by centrifugation andholo-transferrin, and antibiotics (100 U/mL penicillin G
and 100 mg/mL streptomycin sulfate). At the end of the was labeled using 125I. Cultured rat primary MCs were
exposed to varying concentrations of labeled VLDL,incubation period, total RNA was isolated using Trizol
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Fig. 2. Mesangial cell (MC) proliferation in response to very low-den-
sity lipoprotein (VLDL) and lipoprotein lipase (LpL). All cells wereFig. 1. Binding of rat very low-density lipoprotein (VLDL) to primary
quiesced for 24 hours prior to stimulation for 24 hours. Proliferationrat mesangial cells (MCs) at 48C. Abbreviations are: H’ase, 1 IU/mL
is expressed as increase in Quantose dye fluorescence compared withheparanase pretreatment of cells for one hour prior to binding study;
fluorescence after quiescence. N 5 5 to 7 per group. Symbols are: (d)LpL, treatment of cells with 3 mg/mL bovine milk LpL for four hours
LpL 0 mg/mL; (j) 3 mg/mL; (.) 12 mg/mL; *P , 0.05 vs. no addedprior to binding study. N 5 3 to 4 for each VLDL concentration used.
LpL at the same VLDL concentration.Symbols are: (j) VLDL 1 LpL; (.) VLDL 1 LpL 1 heparanase; (r)
VLDL 1 heparanase; (m) VLDL; *P , 0.001 vs. all other groups.
Additionally, some cells were pretreated with hepara-
nase to elucidate the role of HSPG side chains on thewith or without the presence of LpL (3 mg/mL) isolated
proliferative process. The positive control for prolifera-from bovine milk. Because LpL enhancement of lipopro-
tion was the addition of 10% FCS-containing medium.tein binding in vascular endothelial cells has been shown
Proliferation was determined by staining with Quantoseto be dependent on cell surface heparan sulfate, some
fluorescent dye, specific for DNA staining. Data werecells were pretreated with heparanase (1 IU/mL) for one
expressed as the increase in measured fluorescence overhour prior to the binding studies. Binding assays were
pretreatment quiesced values. As shown in Figure 2, acarried out at 48C. Figure 1 shows that while detectable
complex proliferative effect was observed. Without LpL,binding was seen with VLDL alone, this effect was mag-
VLDL exhibited a dose-dependent proliferative effect.nified up to 200-fold by the addition of LpL. Pretreat-
This near-linear dose response was amplified by the addi-ment of the cells with heparanase led to a significant
tion of 12 mg/mL LpL. In contrast, at 3 mg/mL, LpL alonereduction of this LpL amplification, whereas treatment
also markedly stimulated proliferation. Little additionalwith heparanase alone did not affect the VLDL binding
proliferative effect of VLDL was seen at this LpL con-to the cells (P , 0.01 for VLDL 1 LpL vs. all other groups;
centration, with no significant differences seen at anyother groups were not different). These studies show
VLDL concentration. The addition of an anti-PDGFthat, as in vascular endothelial cells, LpL sharply ampli-
antibody to the proliferation assay had no effect, sug-fied the binding of lipoprotein to the cell surface, a pro-
gesting that PDGF is not required for MC proliferationcess dependent in large part on the presence of heparan
(data not shown).sulfate on the cell surface.
Heparanase treatment blocks the LpL amplification ofLpL amplifies the proliferative effects of lipoproteins
VLDL-mediated mesangial cell proliferationon mesangial cells
To determine the role of HSPG in the proliferativeWe next evaluated the effect of LpL on the prolifera-
response, cells were pretreated for one hour with bacte-tive action of lipoproteins. Primary rat MCs were qui-
rial heparanase (Fig. 3). Heparanase alone had no effectesced in serum-free medium for 24 hours and then
on proliferation. Heparanase pretreatment of cells didtreated with either rat VLDL alone (3 to 24 mg/mL) or
the presence of heat denatured LpL (3 to 12 mg/mL). not affect either VLDL (5 mg/mL) or LpL (5 mg/mL)-
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Fig. 4. MC platelet-derived growth factor (PDGF) gene expression in
response to VLDL and LpL. Cells were quiesced as in Figure 2 and
stimulated as in Figure 3 for eight hours. Quantitative PCR was per-Fig. 3. Effect of heparanase digestion on MC proliferation. Cells were
formed using specific primers for PDGF-A chain and the constitutivequiesced as in Figure 2. Cells were stimulated for 24 hours with either
control G3PDH. Results are expressed as ratio of PDGF to G3PDH.10% fetal calf serum or 5 mg/mL VLDL 6 5 mg/mL LpL. Heparanase
N 5 4 to 6 per group. Symbols are: (h) control; ( ) 1 heparanase;is defined as cells treated with 1.0 U/mL bacterial heparanase for one
*P , 0.05 vs. rest.hour prior to stimulation. Symbols are: ( ) 1 heparanase; (h) control;
*P , 0.05 vs. rest.
We also found that LpL alone has a proliferative effect
mediated proliferation when either was added alone, on MCs, just as it does in T cells [22]. Heparanase pre-
but did abolish the amplifying effect of LpL on VLDL- treatment did not effect this LpL stimulation. These data
mediated proliferation, similar to its effect on binding. are consistent with an important role for HSPG in the
LpL–lipoprotein interaction, but not in the isolated bind-LpL augments VLDL-induced growth factor expression
ing of LpL or VLDL to MCs.
To demonstrate a more downstream effect of LpL, Most previously reported effects of LpL have focused
we measured how it affected lipoprotein-induced expres- on enhancement of cellular lipid uptake, by either (1)
sion of PDGF, an important growth factor involved in catalytic hydrolysis of lipoprotein triglycerides with con-
the atherosclerotic and inflammatory response. It is up- sequent release of fatty acids and passive cellular uptake
regulated in MCs under a variety of stimuli, including or (2) receptor-dependent uptake of intact lipoproteins.
normal and oxidized lipoproteins [3, 21]. Primary rat The latter mechanism does not require catalytic activity
MCs were treated with 5 mg/mL VLDL and/or heat dena- of the enzyme [23]. In blood vessels, LpL is thought to
tured LpL (5 mg/mL). PDGF-A chain expression was de- be a crucial mediator of the atherogenic response. There,
termined by quantitative PCR, with G3PDH as the control LpL is expressed and released by smooth muscle cells
constitutive gene. Figure 4 shows that similar to the bind-
and must traverse the lamina interna to the endothelial
ing and proliferation data, VLDL-driven PDGF-A chain
cells, where the LpL eventually binds and mediates lipo-
expression is enhanced (here by 2-fold to 3-fold) in the
protein binding and uptake [24]. This process is enhancedpresence of LpL. LpL alone also induced PDGF, just as it
in atherosclerosis by LpL secretion from circulating mac-did proliferation. As in proliferation, pretreatment with
rophages drawn to the atherosclerotic plaque, a processheparanase did not affect the increased PDGF gene ex-
driven by growth factors such as PDGF [25, 26]. LpL alsopression from either VLDL or LpL alone, but did abolish
acts as a bridge between monocytes and both endothelialthe amplifying effect of LpL.
cells and the endothelial matrix, likely by bridging he-
paran sulfate molecules to cell adhesion molecules on
DISCUSSION the monocytic surface [27].
In our report, cell surface HSPG is shown to be im-This study demonstrates that, like the vascular endo-
portant in several effects of LpL: its action to increasethelium, MC lipoprotein binding is markedly enhanced
binding VLDL to MCs (Fig. 1); its amplification of VLDL-by LpL, and that this enhanced binding leads to enhanced
mediated proliferation by LpL (Fig. 3); and its up-regula-cellular proliferation and expression of the growth factor
tion of VLDL-induced PDGF expression (Fig. 4). ThesePDGF. This amplification by LpL was attenuated by treat-
data suggest that that LpL amplifies the VLDL prolifera-ing cells with heparanase, thus removing their HSPG
side chains, which act to tether LpL to the cell surface. tive response by a mechanism requiring tethering of the
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complex to the cell surface by HSPG. This tethering pre- source of this enzyme. Synthesis of LpL by intrinsic glo-
merular cells cannot be excluded, since normal (macro-sumably brings the lipoprotein into closer proximity to
the various lipoprotein receptors known to reside on the phage-free) glomeruli contain LpL protein that primarily
localizes to the endothelial cells, similar to the distribu-MC [28–32].
Lipoproteins, including VLDL, are known to induce tion seen in the peripheral vasculature [9]. We have de-
tected LpL gene expression, but not bioactivity or pro-proliferation and cytokine expression in cultured MCs
[3]. Both proliferation and PDGF expression are en- tein synthesis, in cultured MCs (data not shown), but
this minimal LpL expression makes them unlikely as ahanced by using minimally oxidized lipoproteins [4, 21].
However, the effects of LpL on these stimulatory effects significant source of glomerular LpL. We did not study
glomerular endothelial cells as a potential source forhave not previously been reported. Notably, we find that
LpL increases both the MC proliferative response and LpL, but this would be unexpected, as vascular endothe-
lial cells do not express LpL mRNA in vivo [9].expression of PDGF by twofold to threefold when com-
pared with the effect of VLDL alone. Nishida et al re- Hence, LpL’s action to enhance lipoprotein–mesangial
interactions occurs by a mechanism independent of LpL’sported a significant proliferative effect of VLDL at only
concentrations over 10 mg/mL [3], while we observed familiar role in triglyceride hydrolysis. Taken together
with the data from lymphocytic cells, our data suggestthat in the presence of LpL, significant VLDL-enhanced
proliferation occurred at 3 mg/mL, with a linear dose that the glomerular inflammatory response is likely me-
diated by LpL, a process involving autocrine/paracrineeffect above that number. Thus, in the presence of LpL,
far smaller VLDL concentrations may have a significant responses to cytokines and circulating lipoproteins. The
proproliferative actions of the molecule may be impor-proliferative effect. A similar effect was seen when VLDL-
induced PDGF expression is examined in the two studies. tant in mediating the lipoprotein-associated progression
of renal glomerular disease. Future studies evaluatingThese differences may be explained by the differing ki-
netics of the VLDL–cell interaction in the presence of the role of lipoproteins in glomerular injury should take
into account the notable physiologic amplification of theLpL, and possibly by the source of VLDL—humans in
the Nishida study and hyperlipidemic rats in ours. The lipoprotein–cellular interaction by LpL.
proliferative response may not be a primary effect of
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